Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Takeda, Royalty - LARVOL DELTA

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (clinicaltrials.gov) - P1 | N=31 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Oct 2025 ➔ Jan 2026 | Trial primary completion date: Oct 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Sarcoma • Solid Tumor • CXCL8

Cabozantinib Franchise Net Product Revenues and Royalties (Businesswire) - "Net product revenues generated by the cabozantinib franchise in the U.S. were $542.9 million during the third quarter of 2025, with net product revenues of $539.9 million from CABOMETYX (cabozantinib) and $3.1 million from COMETRIQ (cabozantinib). Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter ended September 30, 2025, Exelixis earned $46.3 million in royalty revenues."

Sales • Differentiated Thyroid Carcinoma • Hepatocellular Cancer • Renal Cell Carcinoma • Thyroid Gland Medullary Carcinoma

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma (clinicaltrials.gov) - P1/2 | N=28 | Active, not recruiting | Sponsor: John Rieth | Terminated ➔ Active, not recruiting | Trial completion date: Sep 2024 ➔ Dec 2026

Enrollment closed • Trial completion date • Melanoma • Oncology • Solid Tumor • BRAF • PD-L1

A091902: Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2025 ➔ Sep 2026 | Trial primary completion date: Sep 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Angiosarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

CABINET: Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (clinicaltrials.gov) - P3 | N=298 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2025 ➔ Aug 2026

Trial completion date • Carcinoid Tumor • Endocrine Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Solid Tumor • Thymus Cancer

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (clinicaltrials.gov) - P2 | N=134 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Medullary Carcinoma • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

New P1 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=117 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • KRAS • PD-L1 • ROS1

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma (clinicaltrials.gov) - P1/2 | N=28 | Terminated | Sponsor: John Rieth | Trial completion date: Dec 2026 ➔ Sep 2024 | Active, not recruiting ➔ Terminated; Study was terminated early due to changes in the treatment of melanoma

Trial completion date • Trial termination • Melanoma • Oncology • Solid Tumor • BRAF • PD-L1

EXAMINER: A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (clinicaltrials.gov) - P4 | N=247 | Active, not recruiting | Sponsor: Exelixis | Trial completion date: Dec 2023 ➔ Jan 2035

Trial completion date • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

NF113: Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Girish Dhall, MD | Trial completion date: Jul 2033 ➔ Oct 2033 | Trial primary completion date: Jul 2032 ➔ Oct 2032

Trial completion date • Trial primary completion date • Genetic Disorders • Neurofibromatosis • Solid Tumor

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - P2 | N=34 | Active, not recruiting | Sponsor: University of California, Irvine | N=20 ➔ 34 | Trial completion date: Dec 2024 ➔ May 2026

Enrollment change • Trial completion date • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Oncology • Solid Tumor • PD-L1

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer (clinicaltrials.gov) - P2 | N=82 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2025 ➔ Jul 2026 | Trial primary completion date: Dec 2025 ➔ May 2025

dMMR • IO biomarker • pMMR • Trial completion date • Trial primary completion date • Carcinosarcoma • Endometrial Cancer • Oncology • Sarcoma • Solid Tumor • Uterine Cancer

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (clinicaltrials.gov) - P2 | N=17 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2026 ➔ Jul 2026

Trial completion date • Endocrine Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Solid Tumor

Exelixis leans on zanzalintinib as cabozantinib nears patent exp (S&P Global) - "Pending regulatory approval, Zanzalintinib is projected to generate $14 million in risk-adjusted sales from colorectal cancer in 2025, according to Visible Alpha consensus, with analysts assigning a 61% probability of approval in this indication. Broader commercial potential lies ahead, with peak global risk-adjusted sales estimated at $518 million by 2035....If successful across indications, zanzalintinib could reach blockbuster status with risk-adjusted global sales of $1 billion by 2031 and peak sales of $1.6 billion by 2035. Exelixis is hoping the drug will succeed cabozantinib -its current blockbuster sold under the brand names Cabometyx and Cometriq -which generated $1.8 billion in 2024. Sales are projected to rise to $2.2 billion in 2025 and peak at $2.8 billion by 2029, before generic competition begins to erode revenues following patent expiry in 2026."

Patent expiry • Sales projection • Colorectal Cancer • Hepatocellular Cancer • Renal Cell Carcinoma • Thyroid Gland Carcinoma

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update (Businesswire) - "Cabozantinib Franchise Net Product Revenues and Royalties: Net product revenues generated by the cabozantinib franchise in the U.S. were $520.0 million during the second quarter of 2025, with net product revenues of $517.9 million from CABOMETYX (cabozantinib) and $2.1 million from COMETRIQ (cabozantinib). Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter ended June 30, 2025, Exelixis earned $43.4 million in royalty revenues."

Sales • Hepatocellular Cancer • Neuroendocrine Tumor • Renal Cell Carcinoma • Thyroid Gland Carcinoma

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Bradley A. McGregor, MD | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Non Clear Cell Renal Cell Carcinoma • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor

ADVL1622: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (clinicaltrials.gov) - P2 | N=109 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Adrenal Cortex Carcinoma • Alveolar Soft Tissue Sarcoma • Brain Cancer • Clear Cell Renal Cell Carcinoma • CNS Tumor • Endocrine Cancer • Ewing Sarcoma • Genito-urinary Cancer • Hepatoblastoma • Hepatocellular Cancer • Nephrology • Oncology • Osteosarcoma • Renal Cell Carcinoma • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • Wilms Tumor • AXL • MET • RET

Interpreting the Broad Cabozantinib Label for NETs (YouTube) - "At the 2025 American Society of Clinical Oncology Annual Meeting...Neena Vijayvergia, MD...discussed cabozantinib for advanced pancreatic neuroendocrine tumors (NETs) and extrapancreatic NETs....'That's how National Comprehensive Cancer Network guidelines have approved it, and that’s how I use it-in patients who have had one therapy in addition to SSA, so 'third-line' you could say,' Dr. Vijayvergia said."

Video

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial (clinicaltrials.gov) - P1/2 | N=92 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin (clinicaltrials.gov) - P1/2 | N=92 | Not yet recruiting | Sponsor: National Cancer Institute (NCI) | Initiation date: May 2025 ➔ Feb 2026

Trial initiation date • Hepatocellular Cancer • Oncology • Solid Tumor

IMbrella B: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (clinicaltrials.gov) - P3 | N=1000 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial (clinicaltrials.gov) - P2 | N=33 | Recruiting | Sponsor: University of Utah | Trial primary completion date: Apr 2025 ➔ May 2026

Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Martin Voss, MD, ( @MVossMD ) reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ipilimumab plus nivolumab in non–clear cell renal cell carcinoma. #kcsm #RCC | @MSK_DeptOfMed @MSKCancerCenter https://hubs.li/Q03hZH-30